• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

In­tel­lia touts first clin­i­cal out­comes on CRISPR-based AT­TR amy­loi­do­sis as­set

5 months ago
R&D
Cell/Gene Tx

Scot­tish biotech de­buts with ‘Tro­jan horse’ plat­form for can­cer

5 months ago
Startups
R&D

Ei­sai ter­mi­nates Phase 3 tri­al of Dravet drug, cit­ing re­cruit­ment chal­lenges

5 months ago
R&D
Pharma

Trump picks RFK Jr. for HHS; Ab­b­Vie's psych im­plo­sion; Mer­ck tries staving off Sum­mit; and more

5 months ago
Weekly

Il­lu­mi­na seeks to dis­miss share­hold­er law­suit, de­nies se­cret $800M stake

5 months ago
Diagnostics
Law

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

5 months ago
Editor's note
FDA+

Eu­ro­pean drug reg­u­la­tors of­fer wave of pos­i­tive rec­om­men­da­tions fol­low­ing Leqem­bi re­ver­sal

5 months ago
Pharma

Eye­n­ovia halts Phase 3 my­opia tri­al, to con­sid­er sell­ing as­sets

5 months ago
R&D

Boston Phar­ma­ceu­ti­cals hits Phase 2 goals as it tries to keep up with MASH com­peti­tors

5 months ago
R&D

Vi­tal­li ends work on Dae­woong as­set; Alec­tor’s $50M loan

5 months ago
News Briefing

Evotec gains on Halozyme's takeover pro­pos­al

5 months ago
Deals
Manufacturing

ALX On­col­o­gy hires Genen­tech, Mi­rati vet as CMO; Af­ter Car­mot, Heather Turn­er has three new roles on tap

5 months ago
Peer Review

Adap­ti­m­mune to 're­de­fine' it­self as a sar­co­ma biotech, cuts a third of staffers

5 months ago
People
R&D

Eli Lil­ly sues the US gov­ern­ment over its pro­posed 340B re­bate mod­el

5 months ago
Pharma
FDA+

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

5 months ago
People
Pharma

FDA says Merz's so­cial me­dia pro­mo­tion with Nate Berkus is 'mis­lead­ing'

5 months ago
Pharma
Marketing

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

5 months ago
People
Pharma

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

5 months ago
Pharma
FDA+

Arc In­sti­tute pub­lish­es new AI mod­el Evo, cre­at­ing CRISPR sys­tems in a leap for syn­thet­ic bi­ol­o­gy

5 months ago
AI
Cell/Gene Tx

Louisiana's Bill Cas­sidy named next chair of Sen­ate health com­mit­tee

5 months ago
Pharma
Law

Eu­ro­pean Com­mis­sion seeks bio­phar­ma feed­back on No­vo-Catal­ent deal — re­port

5 months ago
Deals
Manufacturing

Lon­za ex­pands bio­con­ju­gates fac­to­ry; WuXi Bio adds ca­pac­i­ty in Ger­many 

5 months ago
Manufacturing

New Zealand clears first clin­i­cal tri­al of epi­ge­net­ic edit­ing for he­pati­tis B

5 months ago
R&D

No­vo Nordisk to phase out its pro­duc­tion of hu­man in­sulin pens glob­al­ly

5 months ago
Manufacturing
First page Previous page 64656667686970 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.